Your clinical team might be two people running three device studies, and the electronic data capture (EDC) platform you inherited still assumes every subject gets a dose rather than an implant or a malfunction report. That mismatch costs time you don't have: forms rebuilt around pharma logic, a Japan post-market surveillance study needing a workaround, and support tickets piling up because nobody can make a mid-study change without a programmer. Viedoc's EDC software is built with device terminology and post-market workflows in mind, not retrofitted from a pharma template. This comparison evaluates five eClinical platforms for MedTech companies across device-workflow adaptability, self-service configuration, Japan post-market surveillance readiness, and suite depth.
You're likely running registries, post-market surveillance, or long-follow-up observational studies alongside your interventional work, and a platform built purely for randomized pharma trials rarely flexes to fit. You need to track serial numbers, lots, and device malfunctions natively, not bolt them on with custom fields that break with every amendment. And if a Japan launch sits on your roadmap, you need post-market surveillance support in place before it becomes a blocker.
Enterprise EDC platforms built for large pharma programs assume in-house programmers and multi-month build cycles, stretching toward 90 days for complex builds on some legacy systems, a pace that doesn't match a lean device team. Consumer-adjacent or academic tools skip the regulatory depth device submissions require. The five platforms below all support regulated device studies, but differ sharply on device-workflow fit, lean-team usability, and Asia-Pacific (APAC) readiness.
Best eClinical solutions: quick comparison
| Platform | Product / module | Overview |
|---|---|---|
| Viedoc | EDC, ePRO, eTMF, RTSM, PMS (Japan) | eClinical suite with 8,000+ studies and a native Japan PMS module. |
| Medidata | Rave EDC / Rave Lite | Enterprise EDC with a Rave Lite tier for Phase I, IV, and MedTech studies. |
| Veeva | Veeva EDC (MedTech) | Vault-based EDC with a dedicated MedTech line, used by Cochlear and Stryker. |
| Castor EDC | Castor EDC / Catalyst | No-code EDC supporting EU MDR post-market and pre-market studies. |
| Medrio | Medrio EDC/CDMS | Cloud EDC/CDMS for Phase I trials, spanning MedTech and biopharma. |
These five eClinical platforms represent the most evaluated options for MedTech and medical device companies, reviewed across device-workflow adaptability, self-service configuration, Japan post-market surveillance readiness, and compliance.
1. Viedoc
Viedoc's EDC software is built around device-specific terminology, with configurable fields for serial numbers, lots, malfunctions, and device events in place of dosing schedules. The platform has powered 8,000+ global studies, including three medical device trials run by MDCE across neurosurgery, ophthalmology, and endocrinology, with around 140 subjects across nine European sites in the first. That device-native design means less time working around forms built for dosing.
The no-code Designer lets your own staff configure and amend studies without a vendor programmer, a direct fit for the one- or two-person clinical operations teams common at device companies. Unlimited user seats mean you're never pricing in headcount as a study scales, and MDCE cited cost, support, and global coverage as factors behind choosing Viedoc.
On compliance, Viedoc is ISO 27001 and SOC 2 certified and supports FDA 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, and HIPAA, hosted on Microsoft Azure with 99.99% uptime. For companies expanding into Japan, Viedoc's post market surveillance software handles booklet data collection, the Kaifu process, and PMDA ERES-compliant reporting inside the standard Designer environment, a capability most SMID-focused vendors don't offer.
"It offers customizable study workflow and tailoring it according to trial specification is easy," says Sanchita V., a Data Manager and verified Viedoc user.
- Study scale: 8,000+ studies run on Viedoc
- Device track record: three medical device studies delivered for MDCE, including a nine-site European neurosurgery trial
- Japan PMS: native post-market surveillance module built for PMDA ERES requirements
- Compliance: FDA 21 CFR Part 11, GDPR, EU Annex 11, HIPAA, ISO 27001, and SOC 2
- Pricing: unlimited user seats, no per-user fees, study-based licensing
- Support: 24/7 support across global offices
2. Medidata
Medidata offers Rave EDC, an enterprise electronic data capture system that anchors the broader Medidata Clinical Cloud alongside modules for randomization and trial supply management (RTSM), electronic trial master file (eTMF), and clinical outcome assessments. For device and diagnostics sponsors specifically, Medidata provides Rave Lite, a simplified, pre-configured version of Rave designed for Phase I, Phase IV, and post-market studies that need to move faster and operate leaner than a full-scale Rave implementation. Rave EDC integrates with the wider Medidata platform for safety data, imaging, and cross-study analytics, and the company states its studies span oncology, cardiovascular, and medical device programs. Medidata's site states Rave was named the most preferred EDC system in the 2025 ISR Benchmarking Report, based on independent sponsor evaluations.
3. Veeva
Veeva provides Veeva EDC as part of a dedicated MedTech product line, distinct from its pharma-focused Vault Clinical suite. The platform is used to design case report forms and edit checks without custom programming, and it supports targeted source data verification and protocol deviation tracking during study execution. Veeva's MedTech customer base includes device manufacturers such as Cochlear, Stryker, Terumo, and BD, and the company states that customers running Veeva EDC have achieved faster study builds and faster implementation of mid-study changes. Veeva EDC connects to Veeva's broader MedTech suite, including electronic trial master file and clinical trial management system applications, for sponsors running an integrated Veeva stack.
4. Castor EDC
Castor EDC is a cloud-based, low-code electronic data capture platform that Castor positions for device companies running European Union Medical Device Regulation (EU MDR) post-market clinical follow-up studies and pre-market clinical investigations. The platform combines EDC with electronic patient-reported outcomes (ePRO), electronic consent, and real-world evidence capabilities on a single database, and Castor states its low-complexity studies can deploy in three to four weeks. Castor's site lists compliance with FDA 21 CFR Part 11, GDPR, and HIPAA, with an exportable audit trail for every data point and action. Castor Catalyst, an add-on capability, uses artificial intelligence to extract structured data from source documents and electronic health records, with human review before entry into the study database.
5. Medrio
Medrio is a cloud-based EDC and clinical data management system (CDMS) built for Phase I and lower-complexity clinical trials, with Medrio's own materials citing a customer base that spans pharmaceutical, biotech, MedTech and medical device, and diagnostics organizations. The platform includes electronic patient-reported outcomes, electronic consent, and randomization and trial supply management alongside its core EDC, configured without a programmer according to Medrio's site. Medrio states studies can be built in under three weeks against an industry average it cites as 12 weeks, with mid-study changes possible in as little as a day. Medrio's support model includes dedicated clinical experts for database build, data management, and regulatory-ready outputs.
What to look for in eClinical platforms for MedTech companies
Device-native study design, not pharma logic with a workaround
A platform designed for dosing-centric pharma trials treats device terminology, procedural visits, and device accountability as add-ons rather than native fields, which shows the first time you need to track a serial number or a malfunction report. That gap means custom field workarounds that break with every protocol amendment and confuse sites unfamiliar with pharma-style forms.
Best-in-class platforms support device terminology, usability assessments, and long-horizon follow-up visits out of the box, without forcing your team to relabel dosing fields. If your platform can't natively track device accountability, expect amendment cycles spent rebuilding logic that should have shipped as standard.
Japan post-market surveillance and APAC regulatory readiness
Japan's post-marketing surveillance requirements, including booklet data collection and the Kaifu review process, are specific enough that most EDC platforms built for the US and EU market simply don't support them natively. For a device company with APAC expansion on its roadmap, this becomes a blocking issue once the first Japan study is scoped.
The strongest platforms offer a purpose-built post-market surveillance module rather than a generic observational-study template stretched to fit, with reporting structures aligned to PMDA ERES guidelines from day one.
Lean-team self-service capability
Device companies frequently run clinical operations with one or two people managing multiple studies, which makes vendor dependency for routine changes a direct hit to velocity. If every amendment or user addition requires a support ticket and a wait, your lean team absorbs the delay, not the vendor.
Look for no-code or low-code study configuration your own staff can run without a dedicated programmer, and confirm whether adding a site or adjusting a field takes hours rather than weeks.
Suite depth across EDC, ePRO, and eTMF
Device studies increasingly combine core data capture with patient-reported outcomes and trial master file management, and running these as three separately licensed systems multiplies your reconciliation overhead. A sponsor collecting patient-reported outcomes alongside site data needs that data in the same validated environment without a manual sync step.
Platforms with genuine suite depth, rather than a core EDC bolted to acquired modules, let you add ePRO software or trial master file capability inside the login your team already knows, instead of maintaining a second vendor relationship.
How to choose the right eClinical platform for MedTech companies
Step 1: Define your study types across the product lifecycle
Map out whether your near-term pipeline includes pre-market investigations, post-market clinical follow-up, registries, or a mix, since these study types carry different visit structures. A platform evaluated only against your current study may not flex when your next protocol is a long-horizon registry.
Step 2: Assess your team's capacity for self-service configuration
Count how many people on your clinical operations team can realistically own study build and amendments, and weigh that against how much vendor-side configuration each platform requires. A platform assuming a dedicated in-house programmer adds a dependency your lean team may not absorb.
Step 3: Scrutinize APAC and Japan requirements against your roadmap
If Japan, China, or other APAC markets appear anywhere in your commercialization plan, verify whether a platform's post-market surveillance and localization support is native or a workaround built for a different market. Confirming this early avoids a costly platform switch mid-program.
Step 4: Evaluate integration overhead across your eClinical stack
Tally how many separate systems and vendor relationships your setup requires for EDC, ePRO, and trial master file management, since each addition brings a validation package and a reconciliation step. Fewer systems generally means less overhead for a lean team to maintain.
Step 5: Choose a platform built for device workflows, not adapted to them
Once you've mapped your study types, team capacity, and regulatory footprint, choose the platform that matches device workflows natively rather than the one you'd configure around. Viedoc is built for exactly this profile, with device-native EDC, an in-house Designer, and a native Japan post-market surveillance module in one suite, and you can book a demo or request a proposal to see it against your own device portfolio.
Frequently asked questions
What is the best eClinical platform for MedTech companies?
Viedoc's EDC software is the best choice for MedTech and medical device companies, combining device-native study design with a no-code Designer that lean clinical teams can run independently and a native Japan post-market surveillance module that most SMID-focused EDC vendors don't offer. Medidata is the enterprise benchmark through its Rave Lite tier for post-market and early-phase device studies, though its broader platform is calibrated for larger organizations with dedicated technical staff. Veeva offers a dedicated MedTech product line with a strong device customer base, suited to sponsors already standardized on the Vault ecosystem.
What should I look for when choosing an eClinical platform for medical device studies?
Prioritize device-native study design over pharma logic adapted after the fact, native Japan post-market surveillance support if APAC expansion is on your roadmap, and no-code configuration your own team can run without a vendor programmer. Suite depth across EDC, ePRO, and trial master file management also matters, since running separate systems for each multiplies your validation and reconciliation burden.
How long does it take to build and deploy a study on a modern eClinical platform?
Timelines vary by platform and study complexity. Self-service study builds on some platforms can go live in as little as a day, while professional-services builds on the same platforms typically run 8 to 12 weeks, averaging around 10 weeks. Enterprise platforms built for large, complex programs can extend toward 90 days for their more complex builds, a pace that rarely fits a lean device team's timeline.
Which eClinical platforms support Japan post-market surveillance studies?
Viedoc offers a dedicated PMS module built specifically for Japan's regulatory requirements, including booklet data collection and Kaifu process management within its standard Designer environment. Most other SMID-focused EDC platforms do not offer a comparable native module and instead require a generic observational-study template adapted for Japan's specific reporting structures. Confirming native support before scoping a Japan study avoids costly rework once the study is underway.
What EDC features matter most for lean MedTech clinical teams?
No-code or low-code study configuration tops the list, since a one- or two-person clinical operations team can't absorb delays waiting on vendor-side programmers for routine amendments. Native device terminology and accountability tracking, unlimited user seats that don't penalize headcount growth, and 24/7 support for questions outside business hours all matter more to a lean team than advanced features built for large, heavily staffed programs.
Can one eClinical platform handle EDC, ePRO, and post-market surveillance for a device program?
Yes, though the depth of that integration varies by vendor. Platforms with genuine suite architecture let patient-reported outcomes and trial master file data flow into the same validated environment as your core EDC, without a manual reconciliation step between separately licensed systems. Verify whether a platform's additional modules are natively built or acquired and loosely connected before assuming they'll behave as one system.
Making the right eClinical choice for MedTech companies
The global eClinical software market is estimated at more than $11 billion in 2025 and is projected to nearly double by 2030, and the platforms reviewed here reflect a range of approaches to that growth, from enterprise suites built around large pharma programs to platforms purpose-built for lean, device-specific workflows. No single platform fits every device sponsor equally well.
Match your choice to your organization's profile: study complexity and phase mix, team size and self-service capability, geographic footprint, and how many separate eClinical systems you're willing to maintain. US-based device teams typically weight speed and return on investment most heavily, while sponsors with EU or APAC commercialization plans tend to weight compliance credentials and vendor stability more heavily.
Switching platforms mid-program carries real validation and retraining costs, so the evaluation you run now is worth doing thoroughly. A platform mismatch that seems minor at study start tends to compound as your device portfolio grows across studies and markets.
Why Viedoc is the best eClinical choice for MedTech companies
If you're managing device studies with a lean team, the operational math is simple: fewer vendor dependencies and fewer systems to validate means more time spent running studies instead of managing tools. Viedoc's EDC software gives your data managers direct, in-house control over study build and amendments through a no-code Designer, without waiting on a vendor programmer for routine changes.
That self-sufficiency extends across the suite. Unlimited user seats mean you're never pricing in headcount as studies scale across sites, and the same Designer environment your team already knows supports ePRO, eTMF, and Viedoc's Japan post-market surveillance module, the only native PMS capability among SMID-focused EDC vendors reviewed here.
Compliance runs deep: ISO 27001 and SOC 2 certified, with FDA 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, and HIPAA support built in, backed by 24/7 support and more than 8,000 studies delivered since Viedoc's founding in 2003.
If that combination of device-native design, lean-team usability, and Japan PMS readiness matches your program, book a demo or request a proposal and the team will walk through your device portfolio against the platform directly.
